High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection

Journal of Infectious Diseases

Volumn 185, Issue 3, 2002, Pages 273-282

  Nichols, W Garett ^a,b   Corey, Lawrence ^a,b   Gooley, Ted ^a   Davis, Chris ^a   Boeckh, Michael ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GANCICLOVIR; METHOTREXATE; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ARTICLE; BACTEREMIA; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFANT; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SERODIAGNOSIS; SEROEPIDEMIOLOGY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; BACTEREMIA; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOSES; RISK; VIRAL LOAD;

EID: 0036467791     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338624     Document Type: Article

References (56)

1. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis
2. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients
3. Cytomegalovirus disease and allograft loss after organ transplantation
4. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
5. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
6. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients
7. Risk factors for cytomegalovirus infection after human marrow transplantation
8. Infections in marrow transplant recipients
9. Cytomegalovirus infection in the bone marrow transplant recipient
10. Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-vs.-host disease
11. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation
12. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial
13. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
14. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
15. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
16. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
17. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
18. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
19. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of CMV disease: Risk factors and outcome
20. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
21. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
22. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
23. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia
24. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
25. Phase II study of busulfan, cyclophosphamide, and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies
26. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
27. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia
28. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
29. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis
30. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
31. Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence
32. 1994 Consensus conference on acute GVHD grading
33. Definitions of cytomegalovirus infection and disease
34. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV)-seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
35. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
36. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis
37. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 Years' experience of the national marrow donor program
38. Longitudinal fluctuation in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD, and CMV disease
39. Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation
40. Cytomegalovirus infection of peripheral blood mononuclear cells: Effects on interleukin-1 and -2 production and responsiveness
41. Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigenrestricted cytotoxic T-lymphocyte activity
42. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus
43. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains
44. + T cells
45. Cytomegalovirus infection is associated with absence of alveolar epithelial cell HLA class II antigen expression
46. Cytomegalovirus inhibits CD14 expression on human alveolar macrophages
47. Role of the monocyte in cytomegalovirus-mediated immunosuppression in vitro
48. Pulmonary macrophage function during experimental cytomegalovirus interstitial pneumonia
49. The effect of cytomegalovirus infection on the adherence of polymorphonuclear leucocytes to endothelial cells
50. Interstitial pneumonitis in bone marrow transplant recipients is associated with local production of TH2-type cytokines and lack of T cell-mediated cytotoxicity
51. Th1 and Th2 cytokines in mice with invasive aspergillosis
52. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis
53. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10)
54. Primate cytomegaloviruses encode and express an IL-10-like protein
55. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation